Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EBT (2022 - 2025)

Axsome Therapeutics' EBT history spans 4 years, with the latest figure at -$28.1 million for Q4 2025.

  • For Q4 2025, EBT rose 62.41% year-over-year to -$28.1 million; the TTM value through Dec 2025 reached -$183.7 million, up 36.02%, while the annual FY2025 figure was -$183.7 million, 36.02% up from the prior year.
  • EBT for Q4 2025 was -$28.1 million at Axsome Therapeutics, up from -$47.2 million in the prior quarter.
  • Across five years, EBT topped out at -$8.6 million in Q1 2023 and bottomed at -$99.0 million in Q4 2023.
  • The 4-year median for EBT is -$60.3 million (2022), against an average of -$56.0 million.
  • The largest annual shift saw EBT soared 78.2% in 2023 before it plummeted 691.35% in 2024.
  • A 4-year view of EBT shows it stood at -$61.2 million in 2022, then plummeted by 61.62% to -$99.0 million in 2023, then grew by 24.4% to -$74.8 million in 2024, then soared by 62.41% to -$28.1 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's EBT are -$28.1 million (Q4 2025), -$47.2 million (Q3 2025), and -$48.9 million (Q2 2025).